Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Haider Mahdi

Showing results (51-60 of 90) with videos related to

Pageof 9
Sort By:
Journal of Gynecology Obstetrics and Human Reproduction|June 27, 2020
Effect of platinum sensitivity on the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in recurrent epithelial ovarian cancerAnthony B Costales, Laura Chambers, Anna Chichura, et al.
Gynecologic Oncology|July 27, 2015
Outcome of neoadjuvant chemotherapy in BRCA1/2 mutation positive women with advanced-stage Müllerian cancerHaider Mahdi, Allison Gockley, Katherine Esselen, et al.
Journal of Surgical Oncology|January 18, 2011
The prognostic impact of the ratio of positive lymph nodes on survival of epithelial ovarian cancer patientsHaider Mahdi, Melissa Thrall, Sanjeev Kumar, et al.
Biorxiv : the Preprint Server for Biology|May 3, 2023
A core NRF2 gene set defined through comprehensive transcriptomic analysis predicts selective drug resistance and poor multi-cancer prognosisGeorge Luo, Harshita Kumar, Kristin Alridge, et al.
Gynecologic Oncology|April 25, 2013
Implementation of tumor testing for lynch syndrome in endometrial cancers at a large academic medical centerJessica Moline, Haider Mahdi, Bin Yang, et al.
Gynecologic Oncology|June 30, 2009
Racial disparities in survival among patients with germ cell tumors of the ovary--United StatesChristopher S Bryant, Sanjeev Kumar, Jay P Shah, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 31, 2023
The promise of combining CDK4/6 inhibition with hormonal therapy in the first-line treatment setting for metastatic or recurrent endometrial adenocarcinomaIsabelle Ray-Coquard, Bradley J Monk, Domenica Lorusso, et al.
Journal for Immunotherapy of Cancer|February 4, 2022
Computational image features of immune architecture is associated with clinical benefit and survival in gynecological cancers across treatment modalitiesSepideh Azarianpour, Germán Corredor, Kaustav Bera, et al.
Anti-Cancer Drugs|September 14, 2021
PARP inhibitors decrease response to subsequent platinum-based chemotherapy in patients with BRCA mutated ovarian cancerPeter G Rose, Meng Yao, Laura M Chambers, et al.
Antioxidants & Redox Signaling|July 19, 2024
A Core NRF2 Gene Set Defined Through Comprehensive Transcriptomic Analysis Predicts Selective Drug Resistance and Poor Multicancer PrognosisGeorge Luo, Harshita Kumar, Kristin Aldridge, et al.
Pageof 9

Showing results (51-60 of 90) with videos related to

Sort By:
Pageof 9
Journal of Gynecology Obstetrics and Human Reproduction|June 27, 2020
Effect of platinum sensitivity on the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in recurrent epithelial ovarian cancerAnthony B Costales, Laura Chambers, Anna Chichura, et al.
Gynecologic Oncology|July 27, 2015
Outcome of neoadjuvant chemotherapy in BRCA1/2 mutation positive women with advanced-stage Müllerian cancerHaider Mahdi, Allison Gockley, Katherine Esselen, et al.
Journal of Surgical Oncology|January 18, 2011
The prognostic impact of the ratio of positive lymph nodes on survival of epithelial ovarian cancer patientsHaider Mahdi, Melissa Thrall, Sanjeev Kumar, et al.
Biorxiv : the Preprint Server for Biology|May 3, 2023
A core NRF2 gene set defined through comprehensive transcriptomic analysis predicts selective drug resistance and poor multi-cancer prognosisGeorge Luo, Harshita Kumar, Kristin Alridge, et al.
Gynecologic Oncology|April 25, 2013
Implementation of tumor testing for lynch syndrome in endometrial cancers at a large academic medical centerJessica Moline, Haider Mahdi, Bin Yang, et al.
Gynecologic Oncology|June 30, 2009
Racial disparities in survival among patients with germ cell tumors of the ovary--United StatesChristopher S Bryant, Sanjeev Kumar, Jay P Shah, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 31, 2023
The promise of combining CDK4/6 inhibition with hormonal therapy in the first-line treatment setting for metastatic or recurrent endometrial adenocarcinomaIsabelle Ray-Coquard, Bradley J Monk, Domenica Lorusso, et al.
Journal for Immunotherapy of Cancer|February 4, 2022
Computational image features of immune architecture is associated with clinical benefit and survival in gynecological cancers across treatment modalitiesSepideh Azarianpour, Germán Corredor, Kaustav Bera, et al.
Anti-Cancer Drugs|September 14, 2021
PARP inhibitors decrease response to subsequent platinum-based chemotherapy in patients with BRCA mutated ovarian cancerPeter G Rose, Meng Yao, Laura M Chambers, et al.
Antioxidants & Redox Signaling|July 19, 2024
A Core NRF2 Gene Set Defined Through Comprehensive Transcriptomic Analysis Predicts Selective Drug Resistance and Poor Multicancer PrognosisGeorge Luo, Harshita Kumar, Kristin Aldridge, et al.
Pageof 9